The recommendation comes after the US Food and Drug Administration (FDA) approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna, which will be available later this week.
Novavax’s protein-based updated COVID-19 vaccine is currently still under FDA review and showed promise against emerging subvariants of COVID-19.
This is the first autumn and winter virus season in the US where vaccines are available for COVID-19, respiratory syncytial virus (RSV) and flu – the three viruses responsible for most hospitalisations.
